Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.

NCT00425282 is registered in ClinicalTrials.gov with SK Life Science, Inc. as lead sponsor.

NCT NCT00425282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00425282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.
Lead sponsor
SK Life Science, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
October 31, 2007
Enrollment
566 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

complex partial seizures, epilepsy, epilepsy, complex partial, epilepsy, focal, seizure disorder